Cancer Research Meeting Calendar Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Welters, M. J. P.
Right arrow Articles by van der Burg, S. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Welters, M. J. P.
Right arrow Articles by van der Burg, S. H.
[Cancer Research 63, 636-641, February 1, 2003]
© 2003 American Association for Cancer Research

Immunology

Frequent Display of Human Papillomavirus Type 16 E6-specific Memory T-Helper Cells in the Healthy Population as Witness of Previous Viral Encounter1

Marij J. P. Welters2, Annemieke de Jong2, Susan J. F. van den Eeden, Jeanette M. van der Hulst, Kitty M. C. Kwappenberg, Sabrin Hassane, Kees L. M. C. Franken, Jan Wouter Drijfhout, Gert Jan Fleuren, Gemma Kenter, Cornelis J. M. Melief, Rienk Offringa and Sjoerd H. van der Burg3

Departments of Immunohematology and Blood Transfusion [M. J. P. W., A. d. J., S. J. F. v. d. E., J. M. v. d. H., K. M. C. K., S. H., K. L. M. C. F., J. W. D., C. J. M. M., R. O., S. H. v. d. B.], Clinical Pharmacy and Toxicology [A. d. J.], Gynecology [G. K.], and Pathology [G. J. F.], Leiden University Medical Center, 2333 ZA Leiden, the Netherlands

Genital human papillomavirus (HPV) infection is common and the majority of infected individuals successfully deal with this virus. Clearance of HPV is presumably mediated by T cells but HPV-16-specific T-cell memory was usually detected in patients with progressive disease and not in healthy subjects, suggesting that HPV-immunity comes too late. We now show the presence of HPV-16 E6-specific memory T-helper (Th) responses in a major fraction (12 of 20) of healthy individuals by application of the IFN-{gamma}-ELISPOT assay. Although nearly all E6-peptides were recognized, the majority of the responders targeted peptide sequences of the COOH-terminal half (E681–158) of HPV-16 E6. In a direct comparison, the presence of HPV-16 E6-specific T cells coincided with HPV-16 E2-specific T-cell reactivity in healthy individuals, whereas hardly any HPV-16 E7-specific Th immunity was found. This indicates that the induction of T-cell reactivity against HPV-16 E7 is suboptimal during infection when compared with that against HPV-16 E2 and HPV-16 E6. In conclusion, the presence of HPV-16 E6-specific Th memory in the healthy population demonstrates that HPV infection leads to T-cell immunity against immediate early proteins expressed during infection. Because this HPV-16 E6-specific T-cell immunity was frequently detected in healthy subjects, our data suggest that the observed IFN-{gamma}-producing proliferating T cells circulating in the peripheral blood play a role in protection against persistent HPV infection and associated development of malignancies.




This article has been cited by other articles:


Home page
 NEJMHome page
G. G. Kenter, M. J.P. Welters, A. R. P.M. Valentijn, M. J.G. Lowik, D. M.A. Berends-van der Meer, A. P.G. Vloon, F. Essahsah, L. M. Fathers, R. Offringa, J. W. Drijfhout, et al.
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia
N. Engl. J. Med., November 5, 2009; 361(19): 1838 - 1847.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Karim, E. S. Jordanova, S. J. Piersma, G. G. Kenter, L. Chen, J. M. Boer, C. J. M. Melief, and S. H. van der Burg
Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma
Clin. Cancer Res., October 15, 2009; 15(20): 6341 - 6347.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. L. Trimble, S. Peng, F. Kos, P. Gravitt, R. Viscidi, E. Sugar, D. Pardoll, and T.C. Wu
A Phase I Trial of a Human Papillomavirus DNA Vaccine for HPV16+ Cervical Intraepithelial Neoplasia 2/3
Clin. Cancer Res., January 1, 2009; 15(1): 361 - 367.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. J. de Vos van Steenwijk, S. J. Piersma, M. J.P. Welters, J. M. van der Hulst, G. Fleuren, B. W.J. Hellebrekers, G. G. Kenter, and S. H. van der Burg
Surgery followed by Persistence of High-Grade Squamous Intraepithelial Lesions Is Associated with the Induction of a Dysfunctional HPV16-Specific T-Cell Response
Clin. Cancer Res., November 15, 2008; 14(22): 7188 - 7195.
[Abstract] [Full Text] [PDF]

Home page
 Br J OphthalmolHome page
D S Hughes, N Powell, and A N Fiander
Will vaccination against human papillomavirus prevent eye disease? A review of the evidence
Br J Ophthalmol, April 1, 2008; 92(4): 460 - 465.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. G. Kenter, M. J.P. Welters, A.R. P.M. Valentijn, M. J.G. Lowik, D. M.A. Berends-van der Meer, A. P.G. Vloon, J. W. Drijfhout, A. R. Wafelman, J. Oostendorp, G. J. Fleuren, et al.
Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity
Clin. Cancer Res., January 1, 2008; 14(1): 169 - 177.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. J.P. Welters, G. G. Kenter, S. J. Piersma, A. P.G. Vloon, M. J.G. Lowik, D. M.A. Berends-van der Meer, J. W. Drijfhout, A. R. P.M. Valentijn, A. R. Wafelman, J. Oostendorp, et al.
Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine
Clin. Cancer Res., January 1, 2008; 14(1): 178 - 187.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Seresini, M. Origoni, F. Lillo, L. Caputo, A. M. Paganoni, S. Vantini, R. Longhi, G. Taccagni, A. Ferrari, C. Doglioni, et al.
IFN-{gamma} Produced by Human Papilloma Virus-18 E6-Specific CD4+ T Cells Predicts the Clinical Outcome after Surgery in Patients with High-Grade Cervical Lesions
J. Immunol., November 15, 2007; 179(10): 7176 - 7183.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. H. van der Burg, S. J. Piersma, A. de Jong, J. M. van der Hulst, K. M. C. Kwappenberg, M. van den Hende, M. J. P. Welters, J. J. Van Rood, G. J. Fleuren, C. J. M. Melief, et al.
Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens
PNAS, July 17, 2007; 104(29): 12087 - 12092.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
K. M. E. Gallagher and S. Man
Identification of HLA-DR1- and HLA-DR15-restricted human papillomavirus type 16 (HPV16) and HPV18 E6 epitopes recognized by CD4+ T cells from healthy young women
J. Gen. Virol., May 1, 2007; 88(5): 1470 - 1478.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
K. H. Kim, W. Greenfield, E. Shotts, and M. Nakagawa
Detection of Human Papillomavirus Type 16-Specific T Lymphocytes by a Recombinant Vaccinia Virus-Based Enzyme-Linked Immunospot Assay
Clin. Vaccine Immunol., April 1, 2007; 14(4): 362 - 368.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. J. Piersma, E. S. Jordanova, M. I.E. van Poelgeest, K. M.C. Kwappenberg, J. M. van der Hulst, J. W. Drijfhout, C. J.M. Melief, G. G. Kenter, G. J. Fleuren, R. Offringa, et al.
High Number of Intraepithelial CD8+ Tumor-Infiltrating Lymphocytes Is Associated with the Absence of Lymph Node Metastases in Patients with Large Early-Stage Cervical Cancer
Cancer Res., January 1, 2007; 67(1): 354 - 361.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. I.E. van Poelgeest, M. van Seters, M. van Beurden, K. M.C. Kwappenberg, C. Heijmans-Antonissen, J. W. Drijfhout, C. J.M. Melief, G. G. Kenter, T. J.M. Helmerhorst, R. Offringa, et al.
Detection of Human Papillomavirus (HPV) 16-Specific CD4+ T-cell Immunity in Patients with Persistent HPV16-Induced Vulvar Intraepithelial Neoplasia in Relation to Clinical Impact of Imiquimod Treatment
Clin. Cancer Res., July 15, 2005; 11(14): 5273 - 5280.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
K. L. Smith, A. Tristram, K. M. Gallagher, A. N. Fiander, and S. Man
Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18
Int. Immunol., February 1, 2005; 17(2): 167 - 176.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Preville, D. Ladant, B. Timmerman, and C. Leclerc
Eradication of Established Tumors by Vaccination With Recombinant Bordetella pertussis Adenylate Cyclase Carrying the Human Papillomavirus 16 E7 Oncoprotein
Cancer Res., January 15, 2005; 65(2): 641 - 649.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. de Jong, M. I. E. van Poelgeest, J. M. van der Hulst, J. W. Drijfhout, G. J. Fleuren, C. J. M. Melief, G. Kenter, R. Offringa, and S. H. van der Burg
Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6
Cancer Res., August 1, 2004; 64(15): 5449 - 5455.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
J. A. DeVoti, B. M. Steinberg, D. W. Rosenthal, L. Hatam, A. Vambutas, A. L. Abramson, M. J. Shikowitz, and V. R. Bonagura
Failure of Gamma Interferon but Not Interleukin-10 Expression in Response to Human Papillomavirus Type 11 E6 Protein in Respiratory Papillomatosis
Clin. Vaccine Immunol., May 1, 2004; 11(3): 538 - 547.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
A. K. Chaturvedi, J. A. Brinkman, A. M. Gaffga, J. Dumestre, R. A. Clark, P. S. Braly, K. Dunlap, P. J. Kissinger, and M. E. Hagensee
Distribution of human papillomavirus type 16 variants in human immunodeficiency virus type 1-positive and -negative women
J. Gen. Virol., May 1, 2004; 85(5): 1237 - 1241.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. J. C. Smyth, M. I. E. van Poelgeest, E. J. Davidson, K. M. C. Kwappenberg, D. Burt, P. Sehr, M. Pawlita, S. Man, J. K. Hickling, A. N. Fiander, et al.
Immunological Responses in Women with Human Papillomavirus Type 16 (HPV-16)-Associated Anogenital Intraepithelial Neoplasia Induced by Heterologous Prime-Boost HPV-16 Oncogene Vaccination
Clin. Cancer Res., May 1, 2004; 10(9): 2954 - 2961.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. J. Baldwin, S. H. van der Burg, C. M. Boswell, R. Offringa, J. K. Hickling, J. Dobson, J. St. C. Roberts, J. A. Latimer, R. P. Moseley, N. Coleman, et al.
Vaccinia-Expressed Human Papillomavirus 16 and 18 E6 and E7 as a Therapeutic Vaccination for Vulval and Vaginal Intraepithelial Neoplasia
Clin. Cancer Res., November 1, 2003; 9(14): 5205 - 5213.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.